Small study to uncover how psoriasis drug tames the immune system
NCT ID NCT05390515
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how the drug tildrakizumab changes immune cells in the skin and blood of people with moderate-to-severe psoriasis. Ten adults will be treated and monitored for three months. The goal is to see how the drug reduces psoriasis severity and what happens to immune function during treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tildrakizumab (an IL-23 blocker given by injection)
What this could lead to
If successful, this could help doctors understand how tildrakizumab works in the body to control psoriasis, potentially improving treatment strategies.
What could go wrong
This is a very small early-phase study with only 10 participants, so results may not apply to everyone. It focuses on immune changes, not long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS VULGARIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94115, United States
Contact